Molecular mechanism of cognitive impairment associated with Parkinson's disease: A stroke perspective

被引:6
作者
Gupta, Sanju [1 ]
Khan, Juhee [1 ]
Ghosh, Surajit [1 ]
机构
[1] Indian Inst Technol Jodhpur IIT, Dept Biosci & Bioengn, Jodhpur 342037, Rajasthan, India
关键词
Stroke; Blood; Dementia; Cognition; Memory; LONG-TERM POTENTIATION; ALPHA-SYNUCLEIN OLIGOMERS; SERUM RESPONSE FACTOR; VASCULAR RISK-FACTORS; ISCHEMIC-STROKE; EXPERIMENTAL-MODEL; NMDA RECEPTOR; CEREBRAL-ISCHEMIA; RAT MODEL; PKM-ZETA;
D O I
10.1016/j.lfs.2023.122358
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Parkinson's disease (PD) is a common neurological illness that causes several motor and non-motor symptoms, most characteristically limb tremors and bradykinesia. PD is a slowly worsening disease that arises due to progressive neurodegeneration of specific areas of the brain, especially the substantia nigra of the midbrain. Even though PD has continuously been linked to a higher mortality risk in numerous epidemiologic studies, there have been significant discoveries regarding the connection between PD and stroke. The incidence of strokes such as cerebral infarction and hemorrhage is substantially associated with the development of PD. Moreover, cognitive impairments, primarily dementia, have been associated with stroke and PD. However, the underlying molecular mechanism of this phenomenon is still obscure. This concise review focuses on the relationship between stroke and PD, emphasizing the molecular mechanism of cognition deficit and memory loss evident in PD and stroke. Furthermore, we are also highlighting some potential drug molecules that can target both PD and stroke.
引用
收藏
页数:16
相关论文
共 197 条
[1]   The role and therapeutic potential of connexins, pannexins and their channels in Parkinson's disease [J].
Ahmadian, Elham ;
Eftekhari, Aziz ;
Samiei, Mohammad ;
Dizaj, Solmaz Maleki ;
Vinken, Mathieu .
CELLULAR SIGNALLING, 2019, 58 :111-118
[2]   Cognitive impairment and memory dysfunction after a stroke diagnosis: a post-stroke memory assessment [J].
Al-Qazzaz, Noor Kamal ;
Ali, Sawal Hamid ;
Ahmad, Siti Anom ;
Islam, Shabiul ;
Mohamad, Khairiyah .
NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2014, 10 :1677-1691
[3]  
[Anonymous], 2019, Indian J. Public Heal. Res. Dev., V10
[4]   Diagnosis and Treatment of Parkinson Disease A Review [J].
Armstrong, Melissa J. ;
Okun, Michael S. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 323 (06) :548-560
[5]   Atorvastatin in prevention of stroke and transient ischaemic attack [J].
Arnarenco, Pierre .
EXPERT OPINION ON PHARMACOTHERAPY, 2007, 8 (16) :2789-2797
[6]   The epidemiology of Parkinson's disease: risk factors and prevention [J].
Ascherio, Alberto ;
Schwarzschild, Michael A. .
LANCET NEUROLOGY, 2016, 15 (12) :1255-1270
[7]   Taking out the garbage: cathepsin D and calcineurin in neurodegeneration [J].
Aufschnaiter, Andreas ;
Kohler, Verena ;
Buettner, Sabrina .
NEURAL REGENERATION RESEARCH, 2017, 12 (11) :1776-1779
[8]   Molecular Mechanisms of Astaxanthin as a Potential Neurotherapeutic Agent [J].
Bahbah, Eshak, I ;
Ghozy, Sherief ;
Attia, Mohamed S. ;
Negida, Ahmed ;
Bin Emran, Talha ;
Mitra, Saikat ;
Albadrani, Ghadeer M. ;
Abdel-Daim, Mohamed M. ;
Uddin, Md Sahab ;
Simal-Gandara, Jesus .
MARINE DRUGS, 2021, 19 (04)
[9]  
Bai Xiang, 2014, J Biochem Pharmacol Res, V2, P185
[10]   Clinical validation of movement disorder society-recommended diagnostic criteria for Parkinson's disease with dementia [J].
Barton, Brandon ;
Grabli, David ;
Bernard, Bryan ;
Czernecki, Virginie ;
Goldman, Jennifer G. ;
Stebbins, Glenn ;
Dubois, Bruno ;
Goetz, Christopher G. .
MOVEMENT DISORDERS, 2012, 27 (02) :248-253